Haj-Mirzaian, Arya
Guermazi, Ali
Pishgar, Farhad
Roemer, Frank W.
Sereni, Christopher
Hakky, Michael
Zikria, Bashir
Demehri, Shadpour
Article History
Received: 10 May 2019
Revised: 10 May 2019
Accepted: 12 June 2019
First Online: 11 July 2019
Compliance with ethical standards
:
: The scientific guarantor of this publication is Dr. Shadpour Demehri.
: AG received funding for consultation from MerckSerono, AstraZeneca, Genzyme, OrthoTrophix, and TissueGene, and as a shareholder and the president and from Boston Imaging Core Lab (BICL). FWR received funding from BICL as a shareholder and chief executive officer (CEO). SD received funding from Toshiba Medical Systems for consultation, and grants for a cone-beam computed tomographic clinical trial from GERRAF, and Carestream Health. The other authors declare that they did not have any competing interests. None of the authors had any competing interests that could influence the results of this work.
: No complex statistical methods were necessary for this paper.
: Written informed consent was not required for this study because we used open-access OAI database. All enrolled subjects in the OAI study gave informed consent.
: Institutional Review Board approval was not required because we used an open-access OAI database. The OAI study has received ethics board approval by the institutional review board at the University of California, San Francisco (OAI Coordinating Center; Approval Number: 10-00532).
: Some study subjects or cohorts have been previously reported in the OAI database and OAI-related articles.
: • Prospective• Observational/case–control• Multicenter study